Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase I Trial
100%
Pediatric Patients
100%
Sargramostim
100%
High-grade Brain Tumor
100%
Pelareorep
100%
Adverse Events
33%
Dose-limiting Toxicity
33%
Leukopenia
33%
Hyponatremia
33%
Inflammation
16%
Glioblastoma
16%
Cancer Causes
16%
Cancer Mortality
16%
Pseudoprogression
16%
Brain Tumor
16%
Immune Cells
16%
Granulocyte Colony-stimulating Factor (G-CSF)
16%
Maximum Tolerated Dose
16%
Glioma Model
16%
Immunological Response
16%
Dose Level
16%
Cohort Design
16%
Oncolytic Adenovirus
16%
Immunomodulatory
16%
Neutropenia
16%
Thrombocytopenia
16%
Diffuse Intrinsic Pontine Glioma
16%
Fever
16%
Hypophosphatemia
16%
Lymphopenia
16%
Flu-like
16%
Hypocalcemia
16%
Level of Consciousness
16%
Medulloblastoma
16%
Tissue Culture Infectious Dose 50
16%
Consistent Changes
16%
Medicine and Dentistry
Phase I Trials
100%
Pediatrics Patient
100%
Intracranial Tumor
100%
Sargramostim
100%
Pelareorep
100%
Adverse Event
33%
Leukopenia
33%
Hyponatremia
33%
Immune Response
16%
Cancer Mortality
16%
Glioblastoma
16%
Ganglioglioma
16%
Immunocompetent Cell
16%
Granulocyte Macrophage Colony Stimulating Factor
16%
Pontine Glioma
16%
Neutropenia
16%
Thrombocytopenia
16%
Lymphocytopenia
16%
Flu Like Syndrome
16%
Inflammation
16%
Hypocalcaemia
16%
Medulloblastoma
16%
Hypophosphatemia
16%
Oncolytic Reovirus
16%